Table 1 Quality description of the included studies according to the criteria of study population (inception cohort, description of source population, description of inclusion/exclusion criteria), follow-up Defactinib cell line (at least 12 months, drop outs, description of completers and drop outs, design of the study), treatment (standardized), prognostic factors (relevant, valid, presented), outcome (relevant, valid, presented), analysis

(univariate, multivariate), and the quality score (good ≥ 13, 9 ≤ moderate ≤ 12) (See also “”Appendix B”" for definitions) Primary author year of publication Study population Follow-up Treatment Prognostic factors Outcome Analysis Quality   Incept Pop Incl Year %Out Descrp Dsgn Stnd Rlvnt Valid Pres Rlvnt Valid Pres Uni Multi Sum Good quality Gross et al. (2009) 0 1 1 1 0 0 1 1 1 1 JQEZ5 1 1 1 1 1 1 13 Moderate quality Bachman et al. (2010) 0 1 1 1 1 1 1 0 1 1 0 1 1 0 1 1 12 Cheng and Cheng (2010) 0 1 1 0 1 0 1 0 1 1 1 1 1 1 1 1 12 Fishbain et al. (1999) 0 1 1 1 0 0 1 1 1 1 1 1 1 1 0 0 11 Gouttebarge et al. (2009a) 1 1 1 1 1 1 1 0

0 0 0 1 1 1 1 0 11 Gross et al. (2006) 0 1 1 1 0 0 1 0 0 0 0 1 1 1 1 1 9 Hazard et al. (1991) 0 1 1 1 0 1 1 1 1 1 1 1 1 1 0 0 12 Kool et al. (2002) 0 1 1 1 1 0 1 1 1 1 1 1 1 1 0 0 12 Lechner et al. (2008)

0 1 1 0 1 1 1 1 0 0 0 1 1 1 0 0 9 Matheson et al. (2002) 0 1 1 0 1 0 1 0 1 1 0 1 1 1 1 1 11 Mayer et al. (1986) 0 1 0 0 1 0 1 1 1 1 1 1 1 1 0 0 10 Strand et al. (2001) 0 1 1 1 0 0 1 1 1 1 1 1 1 1 1 0 12 Vowles et al. (2004) 0 0 1 0 1 0 1 1 1 1 1 1 1 1 0 0 10 Sum score 1 17 17 13 12 8 18 9 15 15 13 18 18 17 11 9   Characteristics of the studies The 18 studies reported on 4,113 participants (median = 147, IQR = 152, range 30–650) (Table 2). Ten studies reported on patients with low back pain, six studies Mannose-binding protein-associated serine protease in patients with musculoskeletal disorders (MSDs) in general, and in one study on patients with upper extremity disorders. In one study, the type or region of the MSDs was not PI3K signaling pathway specified. In at least 78% of the studies (14/18), the MSDs were described as chronic. Seventeen of the 18 studies took place in a rehabilitation setting and one in an occupational setting. The median follow-up period of the studies is 12 months (IQR = 3, range 3–30 months). Type of treatment was described in 50% (9/18) of the studies. The other studies only described the care provider or gave no description.